ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Serology Assay SPR vs Elisa

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon Jul 18, 2021 1:34pm

96 Views

Post# 33566935

RE:Serology Assay SPR vs Elisa

People also have to
keep
in mind that there are 2 separate serology
tests in play here first one is Immusafe test which is basically the work of the Hans frickman lab and a bit of PMN technology. Then there is the PMN serology test which is almost all their own doing. Big difference on the percentage of money that will
come into PMN when they are completed and

<< Previous

Bullboard Posts

Next >>

Victory Battery Metals acquires Utah and Saskatchewan uranium projects